Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Yissum Introduces a Pioneering Vaccine Against CME

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine.

Canine monocytic ehrlichiosis (CME) is a major, potentially fatal, tick-borne dog disease prevalent worldwide.

No commercial vaccine for the disease is currently available and tick control is the main preventive measure against the disease.

Now, Yissum Research and Development Company of the Hebrew University of Jerusalem, introduces a vaccine against CME, which was developed by Professors Shimon Harrus and Gad Baneth, from the Koret School of Veterinary Medicine, Faculty of Agricultural, Food and Environmental Quality Sciences at the Hebrew University of Jerusalem.

The vaccine has proven effective in an experimental study in dogs, which was recently published in the prestigious journal Vaccine.

Profs. Harrus and Baneth developed the vaccine from a proprietary attenuated strain of Ehrlichia canis, the bacteria that causes CME. The efficiency of the attenuated strain as a vaccine was assessed on 12 dogs, which were divided into three groups.

Four dogs were inoculated (vaccinated) with the attenuated Ehrlichia strain twice, four dogs only once and the last group of four dogs served as the control group.

The vaccinated dogs showed no clinical signs after the inoculation, suggesting that the novel vaccine is safe for use and does not induce adverse effects.

When the dogs were infected with a virulent Ehrlichia field strain, the control dogs all developed a severe disease, whereas only three of the eight vaccinated dogs presented mild transient fever and the rest remained healthy.

"Canine monocytic ehrlichiosis is a serious dog disease that can lead to death. Current treatment includes supportive care, and a harsh and lengthy antibiotic treatment, which may not be effective in chronic infections. The vaccine developed by Profs. Harrus and Baneth is the first vaccine to prove effective against this disease," said Yaacov Michlin, CEO of Yissum.

Michlin continued, "The current lack of vaccine for CME, the growing awareness of the market and the growing market needs make this invention particularly attractive, and Yissum is currently looking for commercial partners for further development and commercialization purposes."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anthrax Vaccine Protects Monkeys
Vaccination with the anthrax capsule—a naturally occurring component of the bacterium that causes the disease—completely protected monkeys from lethal anthrax infection, according to a recently published study.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!